June 27, 2016 05:54 AM EDTUpdated September 18, 11:49 PM
Bioregnum
Opinion

The Zer­houni rule: “Every com­pa­ny that ac­quires a plat­form com­pa­ny kills it.”

Why Medi­va­tion makes the per­fect biotech takeover tar­get for Sanofi

Last Jan­u­ary at the J.P. Mor­gan con­fab, I had a chance to sit …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Trump blog: Top HHS spokesper­son re­signs with­in weeks of be­ing sworn in

ICER finds GSK in­halers of­fer ad­van­tages over gener­ic com­peti­tors

No­vo Nordisk signs $354M part­ner­ship with AI-guid­ed biotech for ‘risky’ new meta­bol­ic mech­a­nisms

Af­ter Phase 3 de­pres­sion set­back, Neumo­ra paus­es two tri­als to make changes, scraps an­oth­er

Pro­tag­o­nist, Takeda's prof­it shar­ing deal un­der spot­light af­ter Phase 3 blood dis­or­der tri­al win

sponsored

The per­fect storm: Why every­thing is in place for 2025 to be the year of GxP AI

A service from the Financial Times